Damo: Target price for Shanghai Pharmaceuticals “gain” rating reduced to HK$17

Morgan Stanley released a research report stating that it lowered the target price of Shanghai Pharmaceuticals (02607) by 5.6%, from HK$18 to HK$17, and lowered the company's profit forecast for 2024-2030 by 2%-9%. The main reason was the decline in sales in the manufacturing sector, but the rating still “increased”, mainly due to the complete integration of the platform (manufacturing, distribution, retail) to provide a synergy effect.

新浪港股Apr 18 23:41 ET

Damo: Target price for Shanghai Pharmaceutical (02607) “gain” rating reduced to HK$17

DamocaSea Pharmaceuticals (02607) lowered its 2024-2030 profit forecast by 2%-9%.

Zhitong FinanceApr 18 22:43 ET

Private Companies in Shanghai Pharmaceuticals Holding Co., Ltd (SHSE:601607) Are Its Biggest Bettors, and Their Bets Paid off as Stock Gained 4.8% Last Week

Key Insights Significant control over Shanghai Pharmaceuticals Holding by private companies implies that the general public has more power to influence management and governance-related decisions Th

Simply Wall StApr 18 00:39 ET

UBS: Target price of HK$14.9 for the initial “buy” rating for Shanghai pharmaceuticals

UBS released a research report stating that it initially gave Shanghai Pharmaceuticals (02607) a “buy” rating, with a target price of HK$14.9. Shanghai Pharmaceutical is the second-largest pharmaceutical distributor in China. It accounts for about 9.5% of the market share in 2022. It is optimistic that it has the potential to have differentiated one-stop distribution services and its own pipeline for the production of new drugs. It is predicted that the compound annual growth rate of revenue and profit will reach 10% and 10.6% from 2024 to 2026. Potential positive catalysts include approval of new drugs, strong drug sales expectations, and signing new exclusive distribution agreements with international pharmaceutical companies.

新浪港股Apr 17 03:48 ET

Shanghai Pharmaceutical (02607.HK) held a board meeting on April 26 to approve the first quarter results

Gelonghui, April 16 | Shanghai Pharmaceutical (02607.HK) announced that the board of directors meeting will be held on April 26, 2024 (Friday) to approve (among other things) the first quarter results of the company and its subsidiaries for the three months ended March 31, 2024 and their announcements.

Gelonghui FinanceApr 16 04:42 ET

[Broker Focus] CMB International expects China's pharmaceutical industry to return to healthy growth this year

Jinwu Financial News | CMB International said that since the beginning of the year, the MSCI China Healthcare Index has fallen 22.7%, outperforming the MSCI China Index by 23.3%. Looking ahead to 2024, China's pharmaceutical industry is expected to return to healthy growth as industry regulation is normalized and the impact of the COVID-19 base gradually subsides. The bank continues to be optimistic about BeiGene (06160), Cinda Biotech (01801), Columbotai (06990), Giant Biotech (02367), Gushengtang (02273), and Mindray Healthcare (300760). Additionally, it is recommended to focus on high-dividend stocks with steady performance, such as Regal Healthcare

金吾財訊Apr 16 02:51 ET